Barriers and facilitators to linking and sharing routine health data for research

Research using de-identified health data, generated from electronic health records, prescription records and laboratory public health surveillance systems for example, has great potential to benefit society. In England, our wealth of routine health data sources can help us to understand causes of disease, monitor disease trends, assess the effectiveness of treatments and screening program...

Personalised medicine in action

Back in February, the National Institute for Health and Care Excellence (NICE) published their official evidence-based recommendations for patients diagnosed with colorectal cancer (CRC) to be tested for Lynch syndrome (LS), a hereditary form of the disease. Colorectal cancer, also called bowel cancer, is the fourth most common cancer in the UK, and though LS accounts for no more than 5% of...

Support for regenerative medicines - can the Government and the NHS deliver?

The surprise announcement of a general election on 8th June has generated a flurry of activity from the Commons' and Lords' committees, which have had to wind-up their current inquiries much sooner than expected and release reports on their findings so far. The House of Commons Science and Technology Committee (STC) has had a busy session and their report on regenerative medicine was one of...

Getting serious about science, research and innovation

Plans for a new Industrial Strategy announced in January 2017 set out ten strategic ‘pillars’ intended to support a strong position for Britain in the global economy post-Brexit. 

A vision of the future for personalised healthcare

Earlier this month, a major report was released recommending fundamental changes to the UK National Health Service (NHS).

ctDNA technology in lung cancer: personalised healthcare in action

Personalisation of cancer care, by prescribing drugs that target specific mutations in patients' tumours, is already a reality. For a subset of patients with non-small cell lung cancer (NSCLC) and whose tumours have a mutation in a gene called EGFR, targeted therapies are available.

Technology and innovation – pillars of NHS sustainability

The House of Lords Select Committee’s report The Long-term Sustainability of the NHS and Adult Social Care recommends action to enable necessary ‘transformational change’. This excellent report pulls no punches, and while it would have been easy to shy away from technology to  focus solely on issues that warrant more political and media attention - such as funding, models of care and wo...

How to save the NHS: House of Lords Select Committee proposals

The House of Lords Select Committee on the Long-term Sustainability of the NHS convened in May 2016 has released a report today, the product of a major inquiry including a public consultation and evidence sessions with selected experts (including PHG Foundation Chairman Dr Ron Zimmern). The Long-term Sustainability of the NHS and Adult Social Care sets out their conclusions and recommend...

In these uncertain times

Uncertainty surrounds us, and while this has always been the case, it feels to me that recent political upheavals have led to a greater sense of uncertainty about our futures, and even uncertainty about what we know, or do not know, to be true.

Global collaboration is the key to combating seasonal flu

Sarah James is currently working with the PHG Foundation as a policy analyst, alongside her role as an influenza researcher at the Centre for Pathogen Evolution, University of Cambridge.

Genome editing in medicine - where are we?

As we discussed in a recent blog, the House of Commons Science and Technology Committee's ambitious and wide-reaching inquiry into genomics and genome editing is examining the role that genomic technologies can play in health, agriculture and the environment. The PHG Foundation's written response to the inquiry was one of many sent, and the variety of organisations and individuals responding resul...

The dos and don’ts of non-invasive prenatal testing

A new report from the Nuffield Council on Bioethics supports the use of a non-invasive prenatal testing (NIPT) technique recently approved for use as part of the NHS Fetal Anomaly Screening Programme in pregnancy, as well as setting out some concerns surrounding current commercial provision and potential future uses of testing.